3.75
-0.01 (-0.27%)
| Previous Close | 3.76 |
| Open | 3.77 |
| Volume | 2,263,388 |
| Avg. Volume (3M) | 5,763,606 |
| Market Cap | 1,361,964,544 |
| Price / Sales | 236.90 |
| Price / Book | 8.65 |
| 52 Weeks Range | |
| Earnings Date | 12 Nov 2025 |
| Operating Margin (TTM) | -1,239.23% |
| Diluted EPS (TTM) | -0.910 |
| Quarterly Revenue Growth (YOY) | -54.00% |
| Total Debt/Equity (MRQ) | 19.02% |
| Current Ratio (MRQ) | 4.07 |
| Operating Cash Flow (TTM) | -77.70 M |
| Levered Free Cash Flow (TTM) | -47.04 M |
| Return on Assets (TTM) | -26.04% |
| Return on Equity (TTM) | -79.43% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Atai Beckley N.V | Bearish | Bullish |
AIStockmoo Score
| Analyst Consensus | 3.0 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 1.0 |
| Technical Oscillators | -0.5 |
| Average | 0.38 |
|
ATAI Life Sciences NV is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. Its product candidates include COMP360/Psilocybin therapy, PCN-101/R-ketamine, RL-007/Compound, DMX-1002/Ibogaine, GRX-917/Deuterated etifoxine, VLS-01/DMT, EMP-01/MDMA derivative, RLS-01/Salvinorin A, KUR-101/Deuterated Mitragynine, and DMX-1001/Noribogaine. The business operates geographically in two regions being the United States and Germany. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 7.78% |
| % Held by Institutions | 31.48% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Ally Bridge Group (Ny) Llc | 30 Sep 2025 | 2,287,005 |
| Pale Fire Capital Se | 30 Sep 2025 | 1,080,768 |
| Brown University | 30 Sep 2025 | 718,500 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 15.00 (HC Wainwright & Co., 300.00%) | Buy |
| Median | 14.00 (273.33%) | |
| Low | 12.00 (Needham, 220.00%) | Buy |
| Average | 13.67 (264.53%) | |
| Total | 3 Buy | |
| Avg. Price @ Call | 5.55 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Canaccord Genuity | 22 Oct 2025 | 14.00 (273.33%) | Buy | 5.64 |
| Needham | 13 Oct 2025 | 12.00 (220.00%) | Buy | 5.40 |
| HC Wainwright & Co. | 23 Sep 2025 | 15.00 (300.00%) | Buy | 5.61 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |